Add as a preferred source on GoogleKALA BIO, Inc. Narrows Preliminary Q3 Net Loss to About $0.8 Million
Its preliminary nine-month loss fell to about $4 million. Cash and short-term investments totaled about $7 million at Sept. 30.
KALA BIO, Inc. narrowed its preliminary third-quarter net loss to about $0.8 million from $7.6 million a year earlier, giving investors an early look at its results before a planned SEC filing.
The clinical-stage biopharmaceutical company also posted a preliminary net loss of about $4 million for the first nine months of 2026, compared with $27.7 million in the same period of 2025.
Cash, cash equivalents and short-term investments totaled about $7 million at Sept. 30. KALA BIO had no debt at that date.
The figures are unaudited and remain subject to the company’s financial close procedures and review by its independent accounting firm. KALA BIO expects to file its quarterly report with the SEC on or about Nov. 16.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.